A Study to Evaluate Collecting of Health Related Quality of Life Data in Newly Diagnosed AL Amyloidosis Patients


About this study

The purpose of this study is to evaluate the usefulness of collecting health related quality of life data on newly diagnosed AL amyloidosis patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Willing to provide written informed consent
  • Biopsy proven systemic AL amyloidosis -
  • Age ≥ 18 years
  • Ability to speak and read English
  • Have not started treatment for Al Amyloidosis or who have started treatment for Al Amyloidosis within one month of enrollment

Exclusion Criteria

  • Has initiated AL treatment before 1 month of enrollment including any of the following medications
    • Oral melphalan
    • Bortezomib
    • Thalidomide/lenalidomide
    • Stem cell transplant
      • Having these treatments in the past for another condition (e.g. lymphoma, multiple myeloma) and subsequently diagnosed with systemic AL amyloidosis but is within a month or sooner of starting chemotherapy treatment for AL, are potentially eligible)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Angela Dispenzieri, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer